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HR-HPV infection was a consistent risk factor of high-grade 
CIN in all three groups of women. The length of HOC use was 
not significantly related to high-grade squamous intraepi-
thelial lesions (HSIL)+ Pap (p = 0.069), LSIL+ Pap (p = 0.781) or 
ASCUS+ (p = 0.231). The same was true with the length of 
HOC use and histology CIN3+ (p = 0.115) and CIN2+ (p = 
0.515). Frequently, HOC users have previously shown more 
HPV-related lesions, as well as lower HPV prevalence if they 
were current smokers. But HOC use and time of usage were 
not independent risk factors of either HR-HPV infection or 
high-grade CIN using multiple logistic regressions.  Conclu-
sions: No evidence was found for an association between 
the use of HOC with an increased risk for HR-HPV infection 
or high-grade CIN in this cohort. 
 Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Aims: To evaluate the role of hormonal contraceptives as
a risk factor of high-risk human papillomavirus (HR-HPV), 
cervical intraepithelial lesions (CIN) and cervical cancer in 
our multi-center population-based LAMS (Latin American 
Screening) study.  Methods: A cohort study with  1 12,000 
women from Brazil and Argentina using logistic regres-
sion to analyze the covariates of hormonal contraception 
(HOC – oral, injections, patches, implants, vaginal ring and 
progesterone intrauterine system) use followed by multivar-
iate modeling for predictors of HR-HPV and CIN2+.  Results: 
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 Introduction 
 The implicated increased risk of cervical cancer (CC) 
associated with the use of oral contraceptives or other 
types of hormonal contraception (HOC) is not consistent 
across the reported studies. Many studies report only 
weak association of oral contraceptive with high-grade 
squamous intraepithelial lesions (HSIL) and/or high-
grade cervical intraepithelial lesions (CIN)  [1] . Impor-
tantly, these reports are highly contradictory; there are 
substantially more studies failing to find an association 
than those reporting increased risk  [2] . These apparently 
contentious results may reflect an improved cytological 
surveillance of oral contraceptive users in developed 
countries. This is important because the long-term use of 
oral contraceptives is increasingly common, predispos-
ing these women to potential interactions with high-risk 
human papillomavirus (HR-HPV) infections  [1] . Indeed, 
long-term oral contraceptive use may have an important 
impact in populations that are highly exposed to HPV, 
and these women may need closer surveillance for cyto-
logical abnormalities and HPV infections than women in 
the general population  [1–3] . 
 Recent data on the association between hormonal con-
traceptives and CC have shown a linear dose-response 
relationship; this effect tends to disappear within a time 
interval of 5–10 years after oral contraceptive cessation 
 [3] . According to a recent meta-analysis comparing nev-
er-users of oral contraceptives with continuous current 
users, the relative risks of CC increased with increasing 
duration of use: for periods under 5 years, 5–9 years, and 
10 or more years, respectively, the summary relative risks 
were 1.1 (95% CI 1.1–1.2), 1.6 (1.4–1.7) and 2.2 (1.9–2.4) 
for all women, and 0.9 (0.7–1.2), 1.3 (1.0–1.9) and 2.5 (1.6–
3.9) for women testing HPV-positive  [2] . The results were 
generally similar for invasive and in situ cervical cancers, 
squamous cells and adenocarcinoma. Nevertheless, the 
limitations of these data are recognized and ascribed to 
variable study designs and heterogeneity between the re-
ported results  [2] . 
 Because of this inconsistency, the public health impli-
cations of these findings depend largely on the duration 
of the persistent risk after cessation of the oral contracep-
tive usage  [2] . Among British women, the use of oral con-
traceptives grew rapidly during the 1960s and by the 
1980s, the incidence of CC among British women youn-
ger than 35 years increased by almost 25%. The analyses 
of the odds ratios for CC have suggested that about 23% 
of these cases could be attributable to the use of oral con-
traceptives  [4] . However, because sexual behavior is dif-
ferent among oral contraceptive users, non-oral contra-
ceptive users and non-users of contraception, the assess-
ment of cancer risk must be judiciously evaluated. Indeed, 
several risk factors predispose women to HR-HPV and 
high-grade CIN, and determine the outcome of their cer-
vical disease/HR-HPV infection. As demonstrated re-
cently in a multicenter NIS cohort, the use of oral contra-
ceptives was not an independent risk factor for any of 
these intermediate endpoint markers of cervical carcino-
genesis  [5] . Currently, long-term persistent HR-HPV in-
fection is implicated as the most confident independent 
predictor of high-grade CIN in many studies  [6] . 
 The number of sexual partners, early age at first inter-
course, parity and duration of oral contraceptive were 
found to be significantly associated with an increased 
risk of CC in a recent study conducted in Brazil  [7] , but 
after adjustment, HOC did not remain as an independent 
risk factor. In another cohort study on low-income wom-
en from São Paulo, women who had taken oral contracep-
tives were more likely to have oncogenic HPV infections 
than never-users. Actually, oral contraceptive use was 
strongly and exclusively associated with oncogenic and 
HPV16 infections  [8] . These data are important because 
of the high incidence of HPV infections and high annual 
rates of mortality consequent to CC in South America as 
a whole. Tragically, for several regions, including Latin 
America, the Caribbean and Eastern Europe, cancer of 
the cervix still makes a greater contribution to lost years 
of life than diseases such as tuberculosis, maternal condi-
tions or AIDS  [9] . 
 In the ongoing multicenter, population-based LAMS 
(Latin American Screening) Study testing optional 
screening tools in a cohort of  1 12,000 women in Brazil 
and Argentina, we analyzed hormonal contraception use 
as the potential risk factor for HR-HPV, CIN and CC. 
First, logistic regression was used to assess the covariates 
associated with hormonal contraception use by compar-
ing three groups (including hormonal contraception us-
ers, non-hormonal contraception users and non-users of 
contraception), followed by analysis of the predictors of 
HR-HPV and CIN2+ in univariate and multiple logistic 
regression.
 Materials and Methods 
 General Study Design 
 The ongoing LAMS study is a European Union (EU)-funded 
multicenter screening trial targeting the female populations at 
different risk for CC in two Latin American countries, Brazil and 
Argentina  [10] . In the LAMS study cohort (n = 12,114), eight dif-
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ferent diagnostic tests are compared as optional screening tools in 
a low-resource setting: conventional Pap smear, liquid-based cy-
tology (LBC), visual inspection with acetic acid and with iodine 
solution, cervicography, screening colposcopy, and HR-HPV test-
ing (self-sampling and collected by physician)  [11–15] . 
 The LAMS study is a combination of a population-based, 
cross-sectional and a prospective cohort study of women enrolled 
in regions with different (low, intermediate, high) incidence of CC 
in these two countries. Consecutive series of women at their first 
visit at four clinics (three in Brazil and one in Argentina) were 
screened for cervical HR-HPV infections and CIN, using differ-
ent tests as described before  [10] . Women testing positive with any 
of these techniques were examined by colposcopy at the next vis-
it. Additionally, a 5% random sample of Pap-negative women were 
recalled for a new Pap test at 12 months, as were 20% of those test-
ing HCII negative, to assess the rates of incident Pap smear abnor-
malities and HR-HPV infections  [11, 13] . The women with biopsy-
confirmed low-grade CIN, abnormal Pap or those testing HR-
HPV+ comprised the cohort prospectively followed up for a 
minimum of 24 months, at 6-month intervals. All high-grade le-
sions were promptly treated and followed up for the same period. 
Altogether, 1,011 women were followed up for 38.77  8 4.85 
months. 
 Patients 
 The four clinics examined a total of 12,114 women between 
February 2002 and June 2003, comprising the LAMS study cohort 
 [10] . The mean age of the women at enrolment was 37.9 years 
(range: 14–67; median: 37.7).
 At the first visit, patients were asked to fill in a structured 
questionnaire recording epidemiological characteristics and risk 
factors of CC. This questionnaire included records on the modes 
of contraception used by these women, including the total time of 
hormonal contraception usage. For the present analysis, patients 
were divided into three groups: (a) users of hormonal contracep-
tion (HOC – oral, injections, patches, implants, vaginal ring and 
progesterone intrauterine system), (b) women with no contracep-
tion, and (c) those using other modes of contraception (condom, 
intrauterine device, tubal sterilization, diaphragm, male steriliza-
tion). Furthermore, for statistical analysis purposes, women were 
also divided in two groups: (a) users of HOC and (b) women with 
no hormonal contraception.
 Pap Test Evaluation 
 Cervical cytology was tested in three modes: conventional and 
two different LBC techniques  [11] . Conventional Pap smear was 
taken by all centers, while LBC was tested in one clinic (Leonor 
Mendes de Barros Hospital) only. Interpretation of the smears fol-
lows the Bethesda 2001 system  [16] . In the current analysis, all 
cytology results (conventional and LBC) were considered.
 HPV Testing 
 HPV testing was done by Hybrid Capture 2 (HCII) assay, using 
cervical swabs (collected by a physician) and/or self-sampling de-
vices (tampons), as described previously  [13, 14] . HCII assay was 
performed using the automated HCII test system according to the 
manufacturer’s protocol. The samples were analyzed only for the 
high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 
68. The usual limit of 1 pg/ml of HPV16 DNA was used as the 
positive control (CO). Samples were classified as HR-HPV-posi-
tive, if the relative light unit (RLU) reading of the luminometer 
was equal to or greater than the mean of CO values, i.e. RLU/CO 
 6 1.0 pg/ml was the cutoff for test positivity  [13] . In this analysis, 
only the samples collected by the physicians were included.
 Cervical Biopsies 
 Directed punch biopsies (and cone biopsies) were fixed in 10% 
formalin, and paraffin-embedded. The 5-  m-thick sections were 
routinely stained in hematoxylin-eosin (HE), examined among 
the daily routine in the pathology departments of the four clinics, 
and diagnosed using the commonly agreed CIN nomenclature 
 [10, 13] . CIN1 was considered low-grade CIN, whereas CIN2 and 
CIN3 were classified as high-grade CIN.
 Statistical Analysis 
 Comparison of epidemiological variables across the three 
groups of contraception usage was performed with a   2 test or 
Fisher’s exact test for categorical variables and with the Kruskal-
Wallis test for continuous variables, which in our analysis pre-
sented non-normal distribution. Risk associates for abnormal cy-
tology (HSIL/LSIL cutoffs), HR-HPV and CIN lesions were first 
calculated in univariate logistic regression, with a crude odds ra-
tio (OR) and confidence intervals (95% CI). All significant risk 
factors were entered in a multiple logistic regression (together 
with contraception variables), and the adjusted ORs (95% CI) 
were calculated for two separate outcome variables: HR-HPV in-
fections and CIN2+. In all tests, p  ! 0.05 was regarded as being 
statistically significant. No correction for multiple testing was 
performed. In a previous analysis of our cohort, we identified that 
population characteristics, risk factors and cervical lesions inci-
dence was very similar among the four clinics, so we did not per-
form stratified analysis for each clinic.
 Data were stored and analyzed using the SPSS statistical soft-
ware (version 12.0, SPSS Inc., Chicago, Ill., USA). 
 Results 
 From the whole cohort, 98.73% of the patients com-
pleted the screening phase of the project and have avail-
able data of Pap smear. 97.88% of the women have avail-
able results from Hybrid Capture tests. 
 Initially we analyzed the main characteristics of HOC 
users and non-users to show that they have different key 
epidemiological attributes, representing different sub-
groups ( table 1 ). Several of these characteristics were sig-
nificantly associated with the mode of contraception. 
Most strikingly, users of HOC were younger (mean age 
34.65  8 10.59 years) than women with no contraception 
(42.50  8 11.83) and those using other contraception 
(37.75  8 10.52). HOC users were less likely to be single, 
had the highest prevalence of HR-HPV, and had fewer 
progeny and abortions as compared to the two other 
groups. Another remarkable feature of HOC users was 
their more frequent history of HPV-related lesions, as 
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well as lower HPV prevalence if they were current smok-
ers. 
 Then, we analyzed if risk factors for HPV infection 
and CIN were differently distributed among HOC users 
and non-users ( tables 2 and  3 ). Specifically,  table 2 sum-
marizes the key epidemiological risk factors of high-
grade CIN, stratified according to the mode of contra-
ception. Positive HR-HPV status and abnormal Pap were 
significantly related to CIN in all three groups, whereas 
being single, age at first sexual intercourse,  1 5 lifetime 
sexual partners, number of deliveries, onset of sexual ac-
tivity and ever being a smoker were not universally re-
lated to CIN in the three groups of women. The key epi-
demiological risk factors of HR-HPV infection are shown 
in  table 3 . Age and number of sexual partners were as-
sociated with HR-HPV infection in all three groups. 
Similar data were also calculated for predictors of HSIL 
Pap (data not shown). Then, only HR-HPV+ status was a 
consistent risk factor for HSIL in all three groups of 
women.
Table 1.  Key epidemiological characteristics related to the modality of contraception
Characteristic Users of hormonal 
contraception 
(n = 3,617)
Women with no 
contraception 
(n = 2,637)
Users of other 
contraception 
(n = 5,830)
Signifi-
cance 
p value*
Age 33.23 (25.85; 42.31) 44.50 (32.74; 52.44) 38.20 (29.27; 45.81) <0.0001
Years of education 8.00 (6.00; 11.00) 8.00 (5.00; 11.00) 9.00 (5.00; 12.00) <0.0001
Marital status – single 938/3,610 (26.0%) 1,036/2,636 (39.3%) 1,837/5,824 (31.5%) <0.0001
HR-HPV positive 281/1,423 (19.7%) 139/875 (15.9%) 335/2,106 (15.9%) 0.006
HPV index 0.35 (0.25; 0.68) 0.35 (0.25; 0.57) 0.34 (0.25; 0.58) 0.256
Pap smear
HSIL or worse 50/3,613 (1.4%) 33/2,635 (1.3%) 66/5,825 (1.1%) 0.560
LSIL or worse 107/3,613 (3.0%) 65/2,635 (2.5%) 132/5,825 (2.3%) 0.282
ASCUS or worse 207/3,613 (5.7%) 138/2,635 (5.2%) 290/5,825 (5.0%) 0.283
Final screening diagnosis
CIN3 or cancer 33/3,568 (0.9%) 29/2,605 (1.1%) 56/5,768 (1.0%) 0.748
CIN2 or worse 54/3,568 (1.5%) 35/2,605 (1.3%) 86/5,768 (1.5%) 0.839
Any lesion 159/3,568 (4.5%) 89/2,605 (3.4%) 231/5,768 (4.0%) 0.121
Ever been pregnant 2,859/3,616 (79.1%) 2,080/2,637 (78.9%) 4,772/5,829 (81.9%) 0.0003
Number of deliveries 1.00 (0.00; 2.00) 1.00 (0.00; 3.00) 1.00 (0.00; 2.00) <0.0001
Ever had abortions 1,035/3,616 (28.6%) 963/2,637 (36.5%) 1,897/5,829 (32.5%) <0.0001
Number of abortions 0.00 (0.00; 1.00) 0.00 (0.00; 1.00) 0.00 (0.00; 1.00) <0.0001
Age at first sexual intercourse 18.1583.58 19.1184.73 18.4583.72 <0.0001
Sexually active** 3,355/3,615 (92.8%) 2,098/2,637 (79.6%) 5,359/5,828 (92.0%) <0.0001
Currently, only one sex partner 3,192/3,615 (88.3%) 2,029/2,637 (76.9%) 5,057/5,828 (86.8%) <0.0001
Partners during previous 12 months, n 1.00 (1.00; 1.00) 1.00 (1.00; 1.00) 1.00 (1.00; 1.00) <0.0001
Partners since the first intercourse, n 2.00 (1.00; 3.00) 2.00 (1.00; 3.00) 2.00 (1.00; 3.00) 0.080
Ever had STD 321/3,615 (8.9%) 166/2,636 (6.3%) 440/525 (7.7%) 0.001
Partner ever had STD 335/3,615 (9.3%) 165/2,635 (6.3%) 463/5,828 (7.9%) <0.0001
Ever taken Pap smear 370/3,617 (10.2%) 272/2,636 (10.3%) 610/5,828 (10.5%) 0.931
Lifetime Pap smears, n 4.00 (2.00; 10.00) 5.00 (3.00; 10.00) 5.00 (3.00; 10.00) <0.0001
Time since the last Pap test, months 15.00 (12.00; 24.00) 15.00 (12.00; 24.00) 14.00 (12.00; 24.00) 0.004
History of skin or genital warts 99/3,616 (2.7%) 33/2,634 (1.3%) 118/5,826 (2.0%) 0.0002
History of previous CIN 66/3,616 (1.8%) 17/2,635 (0.6%) 79/5,828 (1.4%) 0.002
Ever been smoker 1,309/3,613 (36.2%) 994/2,634 (37.7%) 2,274/5,829 (39.0%) 0.025
Current smoker 745/3,613 (20.6%) 588/2,634 (22.3%) 1,373/5,829 (23.6%) 0.003
If current smoker, for how long, years 12.00 (6.00; 20.00) 20.00 (10.00; 28.75) 15.00 (7.00; 23.00) <0.0001
Smoked in the past 564/3,613 (15.6%) 406/2,634 (15.4%) 901/5,829 (15.5%) 0.972
If smoked in the past, for how long, years 6.00 (2.00; 13.00) 12.00 (6.00; 20.00) 12.00 (6.00; 20.00) <0.0001
Time since stopped smoking, months 5.00 (2.00; 10.00) 6.00 (3.00; 15.00) 5.00 (2.00; 11.50) <0.0001
V alues presented in median (25th; 75th percentile) when not percentage. * Kruskal-Wallis test for values presented in median and 
2 test for values presented in percentage. ** Last sexual intercourse <12 months.
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 We also performed a multiple logistic regression anal-
ysis to evaluate if use of HOC was a risk factor for HPV 
infection or high-grade CIN ( table 4 ). Age below 35 years, 
Pap and histological abnormalities, never had a Pap 
smear, and marital status, including the number of life-
time sex partners were significant independent risk fac-
tors of HR-HPV. HR-HPV and abnormal Pap smear were 
significantly associated with high-grade CIN. Impor-
tantly, HOC use were not independent risk factors of ei-
ther HR-HPV infection or high-grade CIN in this mul-
tiple logistic regression.
 We also analyzed the time of HOC use as related to 
HR-HPV infection, HSIL/LSIL and CIN outcomes ( ta-
ble  5 ). Interestingly, women testing positive for HR-
HPV reported shorter use of HOC than woman testing 
negative for HR-HPV and this finding was also identi-
fied when we considered only women younger than 35 
years.
 As this study has a follow-up phase, we analyzed if the 
use of HOC influenced the outcome (cure, persistence or 
progression) of HPV infection, abnormal Pap smear or 
CIN lesions ( table 6 ). The baseline HPV/Pap smear status 
Table 2.  Predictors of high-grade CIN in women with different modalities of contraception
Covariate Users of hormonal 
contraception
Women with no 
contraception
U sers of other 
contraception
OR (95% CI) p OR (95% CI) p OR (95% CI ) p
Age <35 years 1.23 
(0.71–2.19)
0.465 0.86 
(0.40–1.83)
0.0688 1.56 
(1.02–2.40)
0.037
Marital status – single 0.91 
(0.49–1.71)
0.781 1.47 
(0.75–2.87)
0.251 2.20 
(1.44–3.37)
<0.0001
HCII test+ 19.24 
(6.42–57.68)
<0.0001 55.25 
(6.97–442.29)
<0.0001 20.30 
(9.53–43.21)
<0.0001
HSIL Pap or worse 181.31 
(90.47–363.34)
<0.0001* 620.61 
(235.66–1,634.35)
<0.0001* 196.62 
(110.33–350.42)
<0.0001*
LSIL Pap or worse 79.97 
(43.75–146.16)
<0.0001* 197.69 
(86.67–450.92)
<0.0001* 73.09 
(45.46–117.51)
<0.0001*
ASCUS Pap or worse 53.42 
(28.78–99.16)
<0.0001* 204.06 
(70.59–589.84)
<0.0001* 48.99 
(30.71–78.16)
<0.0001*
Age at first sexual intercourse 
below mean**
2.69 
(1.31–5.51)
0.005 1.83 
(0.89–3.74)
0.095 1.55 
(0.97–2.46)
0.068
Number of partners >5 since 
first sexual intercourse
1.45 
(0.72–2.9)
0.292 0.46 
(0.11–1.92)
0.423* 2.72 
(1.69–4.35)
<0.0001
Ever been pregnant 1.33 
(0.65–2.74)
0.434 2.08 
(0.73–5.92)
0.160 0.68 
(0.42–1.12)
0.129
Ever had an STD 1.81 
(0.85–3.88)
0.140* 0.42 
(0.01–21.01)
0.585 1.84 
(0.97–3.49)
0.093*
Partner ever had an STD 1.72 
(0.81–3.67)
0.158 0.42 
(0.01–2.56)
0.166 1.37 
(0.68–2.76)
0.369
Previous Pap taken – never had 1.55 
(0.73–3.32)
0.249 1.48 
(0.56–3.85)
0.418 1.25 
(0.66–2.38)
0.480
Ever been smoker 1.65 
(0.97–2.83)
0.064 0.98 
(0.49–1.95)
0.945 1.64 
(1.07–2.51)
0.021
OR  calculated for CIN2+ cutoff with univariate regression. * Fisher’s exact test – all other p values were calculated by Pearson 2. 
** Mean age at first sexual intercourse = 18.51 years.
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did not vary according to the modality of contraception. 
Outcomes of Pap smear abnormalities, HR-HPV infec-
tions and CIN during the follow-up were measured by 
different variables, but no correlation with the modality 
of contraception was observed.
 The prospective follow-up of these women for over 24 
months revealed that incident Pap abnormalities were 
equally frequent among women with baseline abnormal 
Pap, baseline HR-HPV+ test or a combination of both, ir-
respective of their mode of contraception ( table 7 ). The 
Table 3.  Predictors of HR-HPV infection in women with different modalities of contraception
Covariate Users of hormonal contraception Women with no contraception U sers of other contraception
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age <35 years 1.97 (1.49–2.60) <0.0001 1.88 (1.29–2.74) 0.001 2.21 (1.75–2.80) <0.0001
Marital status – single 1.81 (1.37–2.39) <0.0001 1.20 (0.83–1.73) 0.331 2.25 (1.78–2.86) <0.0001
HSIL Pap or worse 21.47 (6.17–74.70) <0.0001* 22.41 (4.71–106.72) <0.0001* 21.19 (9.12–49.25) <0.0001
LSIL Pap or worse 20.90 (9.59–45.51) <0.0001 9.77 (4.19–22.82) <0.0001* 19.09 (10.54–34.60) <0.0001
ASCUS Pap or worse 7.32 (4.80–11.17) <0.0001 7.52 (4.28–13.19) <0.0001 10.00 (6.89–14.50) <0.0001
Age at first sexual intercourse below mean** 1.72 (1.28–2.32) <0.0001 1.32 (0.91–1.91) 0.140 1.80 (1.39–2.33) <0.0001
Partners >5 since first sexual intercourse, n 2.18 (1.57–3.02) <0.0001 1.88 (1.18–3.01) 0.008 2.02 (1.52–2.70) <0.0001
Ever been pregnant 0.51 (0.38–0.68) <0.0001 0.67 (0.44–1.02) 0.060 0.50 (0.38–0.66) <0.0001
Ever had an STD 0.99 (0.64–1.53) 0.954 0.73 (0.34–1.56) 0.412 1.18 (0.82–1.69) 0.419
Partner ever had an STD 1.05 (0.68–1.62) 0.831 0.89 (0.43–1.85) 0.760 1.21 (0.84–1.74) 0.347
Previous Pap taken – never had 1.70 (1.14–2.54) 0.009 1.49 (0.85–2.59) 0.160 1.67 (1.17–2.38) 0.006
Ever been smoker 1.22 (0.93–1.59) 0.153 1.27 (0.88–1.84) 0.194 1.06 (0.84–1.34) 0.679
OR calculated for high-risk HPV detected by Hybrid Capture II with univariate regression. * Fisher’s exact test – all other p values were calculated by 
Pearson 2. ** Mean age at first sexual intercourse = 18.51 years.
Table 4.  Predictors of HR-HPV infections and high-grade CIN in multiple logistic regression analysis
Covariates Outcome: HR-HPV infection O utcome: high-grade CIN
adjusted OR (95% CI) p adjusted OR (95% CI) p
Positive baseline RH-HPV test 8.66 (4.40–17.04) <0.0001
Age <35 years 1.68 (1.39–2.04) <0.0001 1.58 (0.82–3.04) 0.169
HSIL Pap 3.16 (1.23–8.12) 0.017 53.28 (10.90–259.77) <0.0001
LSIL Pap 11.42 (6.62–19.68) <0.0001 13.89 (7.38–26.12) <0.0001
High-grade CIN (CIN2 and above) 8.63 (4.45–16.74) <0.0001
Other contraception 0.94 (0.74–1.19) 0.609 1.18 (0.52–2.69) 0.684
Hormonal contraception* 1.15 (0.90–1.48) 0.258 0.83 (0.34–2.05) 0.699
Ever been pregnant (yes/no) 0.82 (0.65–1.04) 0.063 1.22 (0.56–2.64) 0.608
Deliveries, n 0.99 (0.93–1.05) 0.548 0.99 (0.93–1.05) 0.548
Early onset of sexual activity (≤14 years) 0.91 (0.69–1.19) 0.509 1.13 (0.57–2.23) 0.720
No previous Pap 1.37 (1.04–1.80) 0.023 2.34 (1.03–5.29) 0.040
Ever smoker 1.16 (0.97–1.38) 0.451 1.01 (0.67–1.51) 0.963
Marital status (single) 1.40 (1.16–1.69) <0.0001 1.53 (0.81–2.89) 0.184
2–4 lifetime partners 1.78 (1.45–2.19) <0.0001 0.70 (0.34–1.42) 0.330
>5 partners 2.51 (1.93–3.27) <0.0001 1.25 (0.54–2.88) 0.588
Partner with STD 0.78 (0.55–1.11) 0.177 0.66 (0.20–5.91) 0.499
History of STD 0.76 (0.53–1.08) 0.134 2.09 (0.74–5.91) 0.499
* A dditional subanalysis was performed with HOC time of usage (5-, 10- and 15-year cutoff) with no association to HR-HPV in-
fection or high-grade CIN.
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only exceptions were the group of baseline HR-HPV–/
Pap+ and HR-HPV+/Pap– women with no contracep-
tion, who had a hazard ratio (HR) for incident abnormal 
Pap similar to that of baseline HR-HPV–/Pap– women. 
Women with persistent HPV infections had a higher 
probability of acquiring Pap smear abnormalities during 
the follow-up, regardless of their contraception status. 
Women who acquired incident HR-HPV during the fol-
low-up or had a fluctuating HR-HPV status were not at 
increased risk of Pap smear abnormalities, whereas wom-
en who cleared their baseline HR-HPV infection and 
were users of HOC or other contraceptive methods were 
at a higher risk of acquiring Pap abnormalities. 
 We also analyzed the appearance of CIN during the 
follow-up as related to the baseline status of the women. 
The following variables were associated with an increased 
risk of developing CIN (HR; 95% CI): HR-HPV infection 
(4.17; 1.74–9.96) and LSIL Pap at baseline (1.99; 1.42–
2.80). On the other hand, a large number of variables were 
not related to appearance of CIN, including age  1 35 years, 
baseline HSIL Pap, ever been pregnant, number of deliv-
eries, recent partner, early onset of sexual activity, current 
smoker and being single. The use of other modes of con-
traception (not hormonal) was not protective against in-
cident CIN (0.72; 0.29–1.76). Importantly, no evidence for 
association of HOC usage and disease progression for 
CIN was found (HR: 1.20; 95% CI: 0.50–2.87). 
 Discussion 
 Re-analysis of the data from the International Collab-
oration of Epidemiological Studies of Cervical Cancer 
have recently confirmed that current and recent use of 
combined oral contraceptives is indeed associated with 
an increased risk of invasive CC  [17] . According to these 
sizeable figures from 24 epidemiological studies, the rela-
tive risk in current users augments with increasing dura-
tion of oral contraceptive use. Use for 5 or more years 
(mean: 11.1 years) is associated with doubling of the risk. 
Relative risks were broadly similar among women likely 
not to have been screened and in women likely to have 
been screened, in analyses restricted to HR-HPV+ wom-
en, as well as for CIN3/carcinoma in situ  [17] . 
 In the present cohort of over 12,000 women, we failed 
to confirm any part of the results from this pivotal meta-
analysis  [17] . Our data unequivocally showed that hor-
monal contraceptive use (or length of use) is not an inde-
pendent risk factor of high-grade CIN lesions. It is impor-
tant to note that our study considered users of ‘hormonal 
contraception’ as oral, injections, patches, implants, vag-
inal ring and progesterone intrauterine system, while 
other studies analyzed only users of oral contraceptives. 
We decided to combine all types of hormonal contracep-
tion because we considered that all of them could have 
potential hormonal influence and taking them together 
would give a more robust cause-effect analysis.
 Our data fully confirm the recently reported results 
from another screening trial (NIS – New Independent 
States of the former Soviet Union cohort) in a low-re-
source setting, demonstrating that oral contraceptive use 
was not an independent risk factor of any of the interme-
diate endpoint markers in cervical carcinogenesis  [5] . In-
deed, the possible association of HOC use and CC is made 
far more complex by the strong causal link of HR-HPV 
types to CC  [18] . This is because HPV infections are 
closely related to the sexual behavior of women (and their 
partners), and these adopted sexual habits are in turn 
closely linked with individual women’s preferences for 
contraception modes. Because of this fact, studies claim-
ing a causal association between HOC and CC should be 
able to control for the confounding effect of both HR-
HPV and sexual habits  [18] .
Table 5.  The relation of time of HOC use and HR-HPV infection, 
HSIL/LSIL and CIN outcomes
Outcome Years of HOC 
usage (mean 8 SD)
p 
value
HSIL 9.686.4 0.069
Without HSIL 8.386.9
LSIL 7.986.3 0.781
Without LSIL 8.386.9
CIN1+ 6.885.7 0,013
Without CIN1+ 8.486.9
CIN2+ 8.886.8 0.515
Without CIN2+ 8.386.9
CIN3+ 9.886.5 0.115
Without CIN3+ 8.386.9
HR-HPV+ 6.485.7 0.0001
HR-HPV– 8.586.8
HR-HPV+ women <35 years 4.483.4 0.007
HR-HPV– women <35 years 5.484.3
N o such difference related to HR-HPV status was observed 
among woman aged 35 years or more (p = 0.286). Setting the cut-
off to 30 years, all these differences disappeared.
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 This is nicely illustrated in the present study, where 
most of the key clinical and epidemiological features that 
are known risk factors of CC were significantly associ-
ated with the mode of contraception. For example, HOC 
users when compared to users of no contraception and 
non-HOC users, were younger, had started their sexual 
intercourse earlier, reported more previous STD episodes 
(self and of their partners) and were less prone to be sin-
gle. The HOC users also presented the highest prevalence 
of HR-HPV when compared to the other two groups. 
Thus, we can conclude that HOC users have different life-
style profiles than non-users, which are known to in-
crease the risk of exposure to HPV, which in turn contrib-
utes to an increased risk of CC, not HOC use itself.
 Indeed, when we analyzed the association of these ep-
idemiological factors (e.g. age at first sexual intercourse 
and others) with high-grade CIN, HSIL and HR-HPV, 
this association varied remarkably across the users of 
HOC, non-HOC users and users of no contraception. 
This implicates that the risk factors (and their strength) 
for cervical disease fluctuate depending on the mode of 
contraception because these groups of women have dis-
tinct behaviors and risks associated with their lifestyle 
preferences  [19] .
 In contrast to the recent meta-analysis  [17] , the present 
study failed to establish any increased risk of cervical dis-
ease for the length of HOC usage. Unexpectedly, women 
testing HR-HPV-positive and those having cervical ab-
Table 6.  Baseline status and clinical outcome of cervical lesions and HR-HPV infections as related to the mode of contraception
Hormonal 
contraception, %
Other mode of 
contraception, %
No
contraception, %
p#
Baseline statusa
HR-HPV–/Pap– 21.69 (72/332) 27.47 (100/364) 21.5 (23/107) 0.437
HR-HPV–/Pap+ 13.25 (44/332) 13.46 (49/364) 14.02 (15/107)
HR-HPV+/Pap– 49.4 (164/332) 44.78 (163/364) 43.93 (47/107)
HR-HPV+/Pap+ 15.66 (52/332) 14.29 (52/364) 20.56 (22/107)
Follow-up outcome of HR-HPV infectionb
Always negative 33.0 (89/270) 35.3 (85/241) 31.1 (19/61) 0.302
New infection 2.2 (6/270) 4.1 (10/241) 4.9 (3/61)
Persistence 19.3 (52/270) 17.4 (42/241) 18.0 (11/61)
Cleared 40.4 (109/270) 41.9 (101/241) 44.3 (27/61)
Fluctuation 5.2 (14/270) 1.2 (3/241) 1.6 (1/61)
Follow-up outcome of Pap smear c
Always negative 54.9 (218/397) 55.2 (253/458) 50.7 (76/150) 0.343
New abnormal Pap 14.6 (58/397) 12.4 (57/458) 10.7 (16/150)
Persistent abnormal Pap 4.8 (19/397) 3.1 (14/458) 4.00 (6/150)
Cleared abnormal Pap 22.7 (90/397) 25.5 (117/458) 32.7 (49/150)
Fluctuation (pos-neg-pos) 3.00 (12/397) 3.7 (17/458) 2.00 (3/150)
Follow-up outcome of cases low-CIN biopsy at screening a, c
Progressed  to CIN2+ 4.7 (4/85) 1.00 (1/103) 6.3 (2/32) 0.257
Persisted 10.6 (9/85) 9.7 (10/103) 9.4 (3/32)
Persisted and then regressed 17.6 (15/85) 9.7 (10/103) 6.3 (2/32)
Regressed 67.1 (57/85) 79.6 (82/103) 78.1 (25/32)
Follow-up outcome of cases Pap+ or HC+ and no abnormal biopsy at screening a, d
Progressed to CIN2+ 5.47 (17/311) 1.69 (6/354) 1.68 (2/119) 0.065
Progressed to HR-HPV+/CIN1 6.43 (20/311) 5.93 (21/354) 6.72 (8/119)
No progression to lesion 88.1 (274/311) 92.37 (327/354) 91.6 (109/119)
#  Pearson 2. From the 1,011 patients followed, who have reported the type of contraception: a 803 patients performed HC and Pap 
smear at screening; b 572 patients have the outcome of HR-HPV infection available; c 1,004 patients have the outcome of Pap smear 
available; d 220 patients were low-grade CIN cases at screening and have the outcome of the lesion available; e 784 patients were only 
PAP+ and/or HR-HPV+ at screening (no CIN) and have the outcome available.
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normalities ranging from CIN1 to invasive cancer pre-
sented with shorter times of HOC usage, which can be 
considered a contentious finding. It is noteworthy, how-
ever, that such a univariate analysis does not take into 
account the other potential confounding factors such as 
age, HR-HPV infection and sexual behavior.
 Therefore, because these other variables may be con-
founding factors for cervical disease, we performed me-
ticulous multiple logistic regression modeling with dif-
ferent subpopulations. In two multiple logistic regression 
analyses that included only women who were HOC users, 
we tested the time of HOC usage as a risk factor for HR-
HPV infection and high-grade CIN (dependent vari-
ables), controlled by many other risk factors identified in 
the previous univariate analysis. Importantly, the length 
of HOC use was clearly not associated with an increased 
risk of HR-HPV or CIN2+/CIN3+ outcomes and, in con-
trast to age, abnormal Pap smear, number of sexual part-
ners and no previous Pap smear, appeared among the
independent risk factors of HR-HPV infection and/or 
high-grade CIN.
 The possible association of HOC use and cervical dis-
ease was tested in two additional multiple logistic regres-
sion models that included the use/non-use of HOC as risk 
factor for either HR-HPV infection or high-grade CIN. 
In these multiple logistic regression models, age, abnor-
mal Pap smear, number of sexual partners and no previ-
ous Pap smear were once again associated with HR-HPV 
infection and/or high-grade CIN, while HOC unequivo-
cally did not increase or decrease the risk of either of these 
two outcomes. These results strongly implicate that these 
lifestyle patterns of risk behavior are the factors respon-
sible for conferring the true risk of developing CC, rather 
than the use of HOC themselves.
 However, this is the opposite of the recently reported 
data of Vessey and Painter  [20] , who found a strong posi-
tive relationship between CC incidence and duration of 
oral contraceptive use in a large cohort study that com-
prised the years 1968–2004. The difference to the present 
study, however, is the different endpoint used; instead of 
invasive CC, we used a CIN2+ endpoint because there are 
only few CC cases in the LAMS cohort  [10] . This failure 
to disclose HOC use as a risk factor of CIN2+ (in the pres-
ent study), but a strong one for CC  [17, 20] , could indicate 
that HOC users with high-grade CIN are those at an ex-
tremely high risk for developing CC, i.e. an unknown 
synergistic effect late in cervical carcinogenesis. 
 This hypothesis gets some circumstantial support 
from the findings of the present study, where we also 
examined whether the use of HOC could have an influ-
ence on the outcome of the cervical lesions and HR-
HPV infections during the follow-up. Again, the out-
comes of both cervical abnormalities and HR-HPV in-
fections were completely independent of the mode of 
contraception. This suggests that the effect of HOC (if 
any) in cervical carcinogenesis will become manifest 
only after progression to high-grade CIN, but not evi-
dent before.
Table 7.  Incident Pap smear abnormalities as related to baseline and follow-up HPV status 
Users of hormonal
contraception 
(n = 399)
Women with 
no contraception 
(n = 459)
Users of other 
contraception 
(n = 459)
HR (95% CI) HR (95% CI) HR (95% CI)
Baseline status
HR-HPV–/Pap– Ref Ref Ref
HR-HPV–/Pap+ 6.28 (1.24–31.2) 2.36 (0.24–23.0) 21.75 (6.45–73.33)
HR-HPV+/Pap– 4.93 (2.11–11.5) 3.21 (0.91–11.3) 3.06 (1.57–5.99)
HR-HPV+/Pap+ 6.84 (2.35–19.9) 7.91 (1.74–35.9) 5.15 (2.11–12.55)
Outcome of HR-HPV infection
Always negative Ref Ref Ref
New infection 4.18 (0.91–19.11) NC 1.89 (0.52–6.77)
Persistence 4.70 (2.25–9.81) 6.05 (1.16–31.48) 7.37 (3.50–15.50)
Cleared 2.80 (1.35–5.79) 1.73 (0.33–8.94) 2.85 (1.39–5.82)
Fluctuation 2.78 (0.86–8.90) NC 1.99 (0.25–15.51)
R ef = Referential; NC = not computable; HR = hazard ratio; Pap smear cutoff = ASCUS or higher.
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 The nature of the association between oral contracep-
tives (and/or hormonal contraceptives as a whole) and 
CC should be taken with prudence. CC is known to
be caused by HR-HPV infections, and exposure to HR-
HPV is critically dependent on risky sexual behavior. 
The latter, in turn, is closely associated with the selection 
of the contraception modes (hormonal, barrier, none), 
and it seems likely that women using HOC are more like-
ly to be exposed to HPV than those using e.g. barrier 
methods, or not having sexual intercourse. Interestingly, 
HPV infection is more likely to clear in women whose 
partners use condoms than in those who do not. Thus, 
even if HOC are not causally associated with HPV-in-
duced CC, HPV-positive women who use HOC as a sub-
stitute for barrier methods might be at increased risk 
 [21] . More importantly, long-term HOC and other risk 
factors, such as high parity and early age at first full-term 
pregnancy, were not found to be associated with HPV 
prevalence, but it was suggested that these factors might 
be involved in the transition from HPV infection to cer-
vical lesions  [22] .
 In conclusion, users and non-users of HOC are dis-
tinct groups of women with different lifestyle and sexual 
behaviors that clearly predispose them to different levels 
of risk for acquiring HR-HPV infections or developing 
CC precursors. When analyzed in a population-derived 
cohort of over 12,000 women, carefully controlling for 
confounding factors in this study, the use of HOC itself 
or the length of HOC usage does not appear to increase 
the risk for two important intermediate endpoints of
cervical carcinogenesis: (a) HR-HPV infections and (b) 
high-grade CIN lesions. These data from a low-resource 
setting are robust and may be used as an important refer-
ence for future decisions regarding the prescription of 
HOC in the developing countries. In these countries, 
HOCs are an important option in the prevention of un-
desirable pregnancies, and it is advantageous that their 
use may not be limited by potential implicated risks that 
cannot be proved in well designed studies in local set-
tings.
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